News
Everything Is Going Right for AbbVie: Is It the Best Biotech Stock to Buy Right Now?
Have you ever had one of those days where everything seems to fall into place for you? AbbVie (NYSE: ABBV) is having one of those kinds of years. The big biotech's stock is up more than 40% so far....
Where Will Cara Therapeutics Be in 5 Years?
Cara Therapeutics (NASDAQ: CARA) has been one of the most exciting biotech stocks to watch in 2017, and the excitement has stemmed from both positive and negative developments. By late June, the....
Should You Sell Celgene Stock Following an Analyst Downgrade?
Celgene Corp.'s (NASDAQ: CELG) is arguably one of the globe's most successful biotech companies, yet analysts at investment researcher Morgan Stanley cut their rating on the company from equal....
Why EXACT Sciences Corporation Jumped 13.2% in September
Shares of EXACT Sciences (NASDAQ: EXAS), a diagnostics company focused on colon cancer, rose more than 13% in September, according to data from S&P Global Market Intelligence. While it was a....
Why ImmunoGen, Inc. Dropped Today
Shares of ImmunoGen (NASDAQ: IMGN) are down 11% at 3:29 p.m. EDT after announcing yesterday that it plans to sell 13 million shares through a secondary offering. Investors could be further diluted....
Why Glaukos Corp. Stock Sank 12.8% in September
After management decided to dial back revenue expectations for 2017, shares of Glaukos (NYSE: GKOS), a medical device maker focused on diseases of the eye, tumbled 13% in September, according to....
Big Day on Deck for Flexion Therapeutics
Flexion Therapeutics (NASDAQ: FLXN) is about to find out if its research efforts will pay off. The U.S. Food and Drug Administration is expected to issue a go/no-go decision on its treatment for....
BOIRON : Formulaire de déclaration mensuelle des droits de vote au 30 septembre 2017
Le 5 octobre 2017
Publication
du nombre d'actions composant le capital et du nombre total de droits de vote
(articles L. 233-8 II du code de commerce et 223-16 du règlement général de....
Here's Why Alnylam Pharmaceuticals Rallied 32.7% in September
Powered by encouraging phase 3 results for an important pipeline drug, shares of clinical-stage biotech Alnlyam Pharmaceuticals (NASDAQ: ALNY) , which focuses on RNAi treatments, gained 33% in....
The 2 Surprising Reasons Exelixis, Inc. Lost 17% in September
Shares of Exelixis (NASDAQ: EXEL), a biotech company focused on the development of therapies to treat cancer, plunged 17% during the month of September, according to data from S&P Global....
Why Regeneron Pharmaceuticals Dropped 11.3% in September
Despite sharing a series of positive news items with investors, shares of biotech-giant Regeneron Pharmaceuticals (NASDAQ: REGN) fell more than 11% in September, according to data from S&P....
3 Big Pharma Stocks Set to Succeed
That disclaimer that the Securities and Exchange Commission requires mutual funds to provide to investors isn't one to overlook: Past performance really may not be indicative of future results.....
What Caused Sarepta Therapeutics to Rally 12.6% in September
After reporting early-stage data from a drug candidate for the treatment of Duchenne muscular dystrophy (DMD) on September 6, shares in Sarepta Therapeutics (NASDAQ: SRPT) jumped 12.6% last month,....
3 High-Yield Billionaire Stocks
Billionaire investors know a thing or two about picking stocks. That's why we Fools like to scan our favorite investors' holdings every couple of months to see what they have been buying and....
Why Shopify, Momenta Pharmaceuticals, and MBIA Slumped Today
The stock market saw new highs on Wednesday, even though gains for most major benchmarks were extremely small. Investors are trying to balance their enthusiasm about the U.S. economy and potential....
Here's Why Rigel Pharmaceuticals, Inc. Reversed Course Today
Shares of Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) got off to a rocky start this morning, falling more than 8% before the market digested the details of a recently announced share offering. The....
Here's Why Strongbridge Biopharma Fell as Much as 20% Today
Shares of Strongbridge Biopharma (NASDAQ: SBBP) dropped 20% this morning after the rare-disease therapeutic developer announced the pricing of a share offering. The company will sell 4 million....
Here's Why NewLink Genetics Corp. Stock Is Surging Again Today
Shares of NewLink Genetics Corp. (NASDAQ: NLNK), a clinical stage biotech with an oncology focus, are rising in response to a secondary offering that ended up priced much better than anticipated.....
A Generic Drug Face-Off Sends Mylan Soaring 19%
After the Food and Drug Administration surprisingly gave a green light to the company's Copaxone knockoff, shares in Mylan Inc. (NASDAQ: MYL) are surging 19.5% higher today at 11:30 a.m. EDT. Teva....
Like a Weed, This Marijuana Stock Catapulted Higher by 34% Last Week
If you're an investor, chances are you're well aware that it's been tough to surpass the returns from marijuana stocks over the past year. In late June, the average trailing 12-month return of the....
3 Top Small-Cap Stocks to Buy in October
Even though Halloween is coming, don't let all small-cap stocks scare you. While it's generally true that smaller businesses present higher risks to investors than larger companies do, they may....
Why Shares in AbbVie Soared 18% in September
A patent victory and pipeline advances that could lead to billions in additional sales helped catapult AbbVie Inc. (NYSE: ABBV) shares 18% higher in September, according to S&P Global Market....
Why PTC Therapeutics, Inc. Dropped Today
PTC Therapeutics (NASDAQ: PTCT) fell 10.9% on Tuesday after disclosing data for RG7916 in patients with Type 2 and Type 3 spinal muscular atrophy (SMA).It's been a roller coaster for PTC....
3 High-Yield International Stocks
Most investors fail to look beyond their home country's borders for investment opportunities. That's a shame because great businesses can be found all around the world.Want proof? We asked a team....
Quantum Genomics Releases 2017 First-Half Financial Results and First Nine Months Business Update
Paris & New York, October 3, 2017
Positive results from Phase IIa trial of QGC001 for the treatment of arterial hypertension
Launch of NEW-HOPE Phase II targeted clinical trial in the....